- AIG Slashes US Debt Under Deal With New York Fed
- US Manufacturing Grows Less Than Expected
- Pending Home Sales Have Record Rise; Construction Flat
- Commercial Property Fears Are Overblown: Zell, LeFrak
- Trump: Time to Force Banks to Start Lending
- Accused Fraudster Rothstein Arrested
- What to Expect From Obama's Afghanistan Speech
- Retailers 'Friend' Facebook as Marketing Budgets Shrink
- Good Sign for the Economy: 'Greed' Makes a Comeback
- Predictions 2010: Technology
- Predictions 2010: Consumers
- Predictions 2010
- Predictions 2010: Autos—Two Out of Three Ain't Bad for The Big Three
- Predictions 2010: Real Estate
- Predictions 2010: Analyst Tony Fratto
- Predictions 2010: Analyst Vince Farrell
- Predictions 2010: Economy & Markets
- Predictions 2010: Analyst Tony Crescenzi
MOST SHARED
- Commercial Property Fears Are Overblown: Zell, LeFrak
- Good Sign for the Economy: 'Greed' Makes a Comeback
- Dubai Stocks Could Fall a Further 30%: Charts
- Dubai Markets Close Sharply Lower for Second Day
- Manufacturing in Focus as Bulls Call for Turn in Dollar
- US Manufacturing Grew Less Than Expected in November
- More Late on Auto Loan Payments in Third Quarter
- AIG Slashes US Debt Under Deal With New York Fed
- Oil Companies Look to the Future in Iraq
- Charts: Dollar Could See Solid Rebound
Text Size 
Baxter [BAX
Loading...
()
] researchers revealed positive mid-stage test results on an intravenous drug, Gammagard, that's already in late-stage development in a very small number of patients.
According to test reports, the plasma-based drug appears to improve memory and quality of life—or at the very least, stabilize and stop the rate of loss of memory.
Baxter's stock rose almost 2 percent when the data was released. (See the accompanying video for more.)
Meanwhile, Elan [ELN
Loading...
()
] and Wyeth’s [WYE
Loading...
()
] shares plunged Wednesday after word that mid-stage test results on a potentially first-of-its-kind Alzheimer’s drug, Bapineuzumab, raised safety issues.
However, Elan CEO Kelly Martin told CNBC he was confident in Bapineuzumab.
"There are obviously some gaps between the market interpretation and what we know,” Martin said.
Additionally, a small biofirm, Medivation [MDVN
Loading...
()
], showed new data on an anti-histamine that in a large study appears to preserve memory in mild to moderate Alzheimer’s patients.
Print
Email
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- What do the gifts from the 12 Days of Christmas cost this year, and how do they compare to 2008?
- A conservative author aims to remind readers why capitalism works for the common good.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.
Data is a real-time snapshot *Data is delayed at least 15 minutes